Health Care · Biological Products, (No Diagnostic Substances)

RVMD Revolution Medicines Inc SEC Filings & Insider Trading Activity 2026

company
CIK 1628171104 filings

RVMD at a glance

Revolution Medicines Inc (RVMD, SEC CIK 1628171) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Revolution Medicines Inc (RVMD) reported revenue of $0 and a net loss of $1.1 billion. Diluted EPS was -$5.95.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Revolution Medicines Inc (RVMD) shares worth $12.4 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Kelsey Stephen Michael on November 16, 2026 of 11,542 shares at $166.75 per share.
  • In the last 90 days, RVMD insiders reported 0 open-market purchases ($0) and 74 open-market sales ($60.0M) on Form 4, a net sale of $60.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 74 sells
Net −$60.0M
13F holders
34 funds
$12.4B · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $197.6M, versus $0 YoY, reflecting RASONQUE launch and channel stocking
  • Net loss $407.5M vs $305.2M YoY, operating margin -188.9% vs not applicable
  • Best program RASONQUE revenue $197.6M; highest R&D increase zoldonrasib, $78.1M vs $30.9M YoY
  • Cash, equivalents and marketable securities $3.7B; operating cash use $1.2B for nine months
  • Outlook: R&D and SG&A expected to increase, RASONQUE sales partial-quarter and future cost of sales percentage rising

Risk Factors

  • Newly added commercialization risk: RASONQUE U.S. launch in August 2026 created limited commercial-scale manufacturing and marketing experience
  • Most material financing update: $250.0 million Term Loan Facility tranche drawn in October 2026, secured by substantially all assets including intellectual property
  • Regulatory pricing risk: September 2026 Globe rule would tie Medicare rebates to most-favored-nation pricing, subject to legal challenges
  • Near-term market risk: RASONQUE competes with established chemotherapy and targeted therapies with greater commercial infrastructure
  • Financial risk: $500.0 million 2033 Notes plus approximately $572.3 million royalty liabilities outstanding at September 30, 2026

AI summary of the RVMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • RASONQUE U.S. launch generated $197.6 million revenue in roughly five weeks, establishing Revolution Medicines as a commercial-stage oncology company
  • More than 5,000 patients received RASONQUE, while payer claims covered over 90% of U.S. PDAC lives, supporting early access momentum
Filed Oct 13, 2026Full analysis →

Item 8.01: Other Events

  • FDA approval of RASONQUE triggered $250.0M Tranche A borrowing from Royalty Pharma
  • $5.0M draw fee, floating interest at three-month Term SOFR plus 5.75%, with 3.50% floor

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 flags a new direct financial obligation tied to the Royalty Pharma Tranche A Loan
  • Loan terms, borrowing amount, interest rate, maturity and purpose appear under Item 8.01
Filed Sep 1, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 references Item 1.01 for the underlying lease-related financial obligations
  • Potential future commitments tied to Phase II closing, leases, build-out, relocation and occupancy costs

Item 1.01: Entry into a Material Definitive Agreement

  • New headquarters: 672,000 square feet across four Redwood City buildings, with staggered occupancy beginning September 2027
  • Initial lease terms through September 2042, with three additional five-year extension options at fair market rent

AI summaries of RVMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RVMD

Don't miss the next RVMD filing

  • Alerts as it files. A push when RVMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RVMD, by share count.
  • Ask anything. An AI agent that reads every RVMD filing and answers with sources.

RVMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kelsey Stephen MichaelSellNov 16, 2026$166.75
Kelsey Stephen MichaelSellNov 16, 2026$171.65
Kelsey Stephen MichaelMNov 16, 2026-
Kelsey Stephen MichaelSellNov 16, 2026$167.66
Kelsey Stephen MichaelSellNov 16, 2026$169.46
Kelsey Stephen MichaelSellNov 16, 2026$170.40
Kelsey Stephen MichaelMNov 16, 2026$18.56
Kelsey Stephen MichaelSellNov 16, 2026$168.64

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$11.6M$0$0
Operating Income--$689.5M-$1.2B
Net Income-$436.4M-$600.1M-$1.1B
Net Margin-3768.3%--
Balance Sheet
Total Assets-$2.6B$2.4B
Equity$1.8B$2.3B$1.6B
ROE-23.9%-26.5%-69.3%
Per Share
EPS-$-3.58$-5.95
Cash Flow
Operating CF--$557.4M-$897.7M
CapEx$7.7M$10.3M$16.0M

Source: XBRL data in Revolution Medicines Inc (RVMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RVMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RVMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$12.40B
Q2 202636$13.12B
Q1 202634$5.80B
Q4 202529$4.73B
Q3 202531$2.95B
Q2 202531$2.28B
Q1 202526$1.66B
Q4 202422$1.70B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 243 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RVMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Oct 28, 2026--
8-KOct 13, 2026Analysis-
4Oct 1, 2026--
4Sep 29, 2026--
4Sep 28, 2026--
4Sep 24, 2026--
4Sep 22, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 18, 2026--
4Sep 15, 2026--
4Sep 14, 2026--
4Sep 10, 2026--
4Sep 2, 2026--

Related Health Care companies

All Health Care →

RVMD SEC filings: frequently asked questions

Are RVMD insiders buying or selling?

In the last 90 days, Revolution Medicines Inc (RVMD) officers, directors and 10% owners reported no open-market purchases and 74 open-market sales worth $60.0 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RVMD stock?

As of September 30, 2026, the largest Revolution Medicines Inc (RVMD) holders among the 13F filers tracked by SignalX were BlackRock ($2.8 billion), Vanguard Capital Management LLC ($1.9 billion), Vanguard Portfolio Management LLC ($1.7 billion), State Street Corp ($1.0 billion), JPMorgan Chase & Co ($973.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RVMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Revolution Medicines Inc (RVMD) reported revenue of $0 and a net loss of $1.1 billion. Diluted EPS was -$5.95. The figures come from the XBRL data in the 10-K.

What did RVMD report in its latest 8-K?

Revolution Medicines Inc (RVMD) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest RVMD SEC filings?

Revolution Medicines Inc (RVMD) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is RVMD's SEC CIK number?

Revolution Medicines Inc (RVMD)'s SEC Central Index Key (CIK) is 1628171. EDGAR lists every RVMD filing under that number.

Ask anything about RVMD

The research agent reads RVMD's filings, financials, insider trades and 13F holders, then answers with sources.